Global Stem Cells Group announces the opening of a new Stem Cell Center in Bandung, Indonesia
Miami, FL, December 12, 2022 – Global Stem Cells Group (GSCG) is pleased to announce the opening of a new Stem Cell Center in Bandung, Indonesia in partnership with the Dr. Yanti Aesthetic Clinic. This joint venture will be the second in the country as they already have another facility in the stunning City of Surabaya.
The New Global Stem Cell Group Facility is Expected to Transform the Regenerative Medicine Field
The GSCG’s new center in Bandung aims to increase awareness about the benefits of regenerative medicine. Its launch strengthened the relationship between GSCG and the Dr. Yanti Aesthetic Clinic. This new facility is expected to transform regenerative medicine in the following ways:
- Offering accessible stem cell therapy to Indonesians;
- Promoting regenerative medicine technology; and
- Inspiring other doctors and industry experts to explore regenerative medicine.
Top Government Officials Attended the Launch of the Global Stem Cell Group Office in Bandung
The launch of the new Global Stem Cell Group facility in Bandung was a remarkable event in the medical field. The Minister of Tourism was among the top officials that witnessed the launch. Furthermore, the office of the Vice President sent several representatives.
What the President of Global Stem Cell Group Has to Say
Benito Novas, the president of the GSCG, was among the top industry specialists that graced the launch of the company’s second facility in Indonesia. According to him, GSCG wants to make regenerative medicine readily available for patients worldwide. Likewise, the company is encouraging more doctors to adopt stem cell therapy’s clinical and aesthetic applications in their work.
Benito Novas said: “We are dedicated to making it possible for both doctors and patients in all parts of the world to experience the benefits of regenerative medicines. The company is expanding and establishing itself as a market leader.”
The Director of the Dr. Yanti Aesthetic Clinic Appreciates GSCG
Dr. Yanti Kushmiran, director of the DR. Yanti Aesthetic Clinic, is once again honored to be part of this step into the future of regenerative medicine with its second Stem Cell Center in Indonesia together with the leading company Global Stem Cells Group.
Regarding this new clinic, Dr. Yanti says “We are honored to be part of GSCG, which has a more than 10-year track record in the market and a strong international reputation and to open a second cell therapy and regenerative medicine center facility under the Stem Cell Center brand. We will be able to provide more services to our patients as a result of this new partnership.”
Another GSCG Clinic is Opening in Indonesia by January 2023
The Global Stem Cell Group will continue increasing patients’ access to advanced regenerative medicine. As a result, the company plans to open another branch in Jakarta, the Capital of Indonesia. GSCG and its partners plan to launch this third facility in January 2023.
About Global Stem Cell Group
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
- Published in Press Releases
ISSCA to Host 6th Annual Regenerative Medicine Symposium in Buenos Aires, Argentina Aug. 16-17, 2019
ISSCA’s 2019 “Applications of Cell Therapies in Medicine and Aesthetic Surgery” symposium agenda to focus on allogeneic compounds in the regenerative medicine industry.
MIAMI, Dec. 18, 2018—The International Association for Stem Cell Application (ISSCA) has announced plans to host its sixth annual “Applications of Cell Therapies in Medicine and Aesthetic Surgery” regenerative medicine symposium in Buenos Aires, Argentina August 16-17, 2019. The focus of the symposium agenda will be allogeneic compounds—how they have changed the regenerative medicine industry, and how the industry will accommodate the challenges allogeneic therapies present.
The international symposium is part of ISSCA’s mission to support a paradigm shift in healthcare from traditional to regenerative medicine in the 21st Century and provide cutting-edge information on developments in all areas of stem cell research.
In 2018, the 5th annual symposium was held in three international cities—Buenos Aires, Istanbul, Turkey and Caracas, Venezuela. Each event exceeded organizers’ expectations both in attendance numbers and active participation. More than 200 physicians from the U.S., South America, Europe, the Middle East and Asia attended the symposiums in Istanbul and Caracas, and more than 350 physicians from around the world attended in Buenos Aires.
The high attendance and enthusiastic participation of attendees at the Argentina symposium, which was held at the Universidad de Buenos Aires, compelled ISSCA organizers to reconsider their multi-country strategy and host the event exclusively in Buenos Aires in 2019. In addition, ISSCA has committed to hosting the annual symposium in Buenos Aires for the next six consecutive years.
In keeping with ISSCA’s commitment to supporting the most current advances in stem cell and regenerative medicine discoveries, the 2019 symposium will explore the impact the acceleration of allogeneic compounds have had on the industry, new challenges they bring to the market, and promising new therapies they are expected to provide to an ever-widening spectrum of diseases and medical conditions.
A group of renowned international speakers, experts in the field of stem cell and regenerative medicine including the latest advances in allogeneic therapies, will lead rigorous scientific discussions and Q&A sessions with physicians in attendance. In Addition, ISSCA has invited representatives from [name of’ lab?], one of the world’s largest regenerative medicine labs to share their experiences and knowledge with physicians representing the global medical community in attendance,
The symposium will incorporate the biology, medicine, applications, regulations, product development, and commercialization of stem cells and regenerative medicine solutions.. In addition, business opportunities, industry challenges, and potential strategies for overcoming those challenges will be discussed.
The event venue in Buenos Aires will be announced shortly.
To learn more about the ISSCA Buenos Aires symposium and to reserve a seat, visit the stemcellconference.org website, email info@stemcellsgroup.com, or call +1305 560 5337.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a 
multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training. and certification.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
###
Regenerative medicine symposium allogeneic compounds
- Published in Press Releases
ISSCA to Host Sponsored Regenerative Medicine Symposium in Caracas, Venezuela Dec. 1, 2018
ISSCA announce plans to host the World Symposium on Regenerative Medicine and Cell Therapies in Venezuela Dec. 1, 2018, Event organizers will sponsor 50 percent of event fees to provide most physicians in economically-strapped Venezuela with access to regenerative medicine education.
MIAMI, Sept. 28 2018—International Society for Stem Cell Application (ISSCA), in keeping with its mission to promote regenerative medicine in clinical applications and provide clinical stem cell therapy training to physicians worldwide, announces plans to host the World Symposium on Regenerative Medicine and Cell Therapies: “Adult Stem Cells. The immediate future of Medicine” in Caracas, Venezuela December 1, 2018.
Global Stem Cells Group (GSCG) CEO and ISSCA Vice President Benito Novas says the symposium is an important event for both organizations’ commitment to spreading knowledge and physician training in regenerative medicine to medical professionals worldwide. This commitment includes strategies to accommodate countries like Venezuela that lack the resources to train physicians to implement regenerative medicine procedures in clinical settings.
“Global Stem Cells Group understands the difficult financial conditions that are depriving Venezuelans of essential advances in medicine including cellular therapies that are being used to improve the quality of life for patients in countries around the world,” says Novas. “GSCG is committed to providing regenerative medicine training and education to physicians everywhere.”
According to Novas, the dire state of Venezuela ‘s health care system is a call-to-action for ISSCA and Global Stem Cells Group Group is sponsoring the event and funding 50 percent of event fee costs to ensure most Venezuelan physicians can attend.
The goal is to make economically and therapeutically viable regenerative medicine therapies available to Venezuelans by training and educating physicians throughout the country in stem cell therapies and protocols they can provide to patients in their clinics.
“The opportunity to sponsor this important symposium is very gratifying to us, as it resonates with GSCG’s core mission to bring regenerative medicine to countries around the world,” Novas says. “We’re driven by our conviction that stem cell medicine will bring transformative changes to the healthcare industry at a global level.
“Regenerative cellular therapies are already replacing invasive treatment practices and improving quality of life outcomes for patients suffering from illnesses and injuries that are not treatable with traditional medicine, he says. “Global Stem Cells Group is motivated to take this first step toward making economically and therapeutically viable regenerative medicine therapies available to Venezuelans.
“This symposium is an important step toward making regenerative medicine education and training available to physicians in Venezuela.”
Symposium topics of focus include:
- Clinical applications for regenerative medicine to treat sports injuries
- Stem cell procedures to treat erectile dysfunction
- How mesenchymal stem cells contribute to renal repair in the treatment of acute tubular epithelial injury
- Management of aging at the cellular level
- Managing advanced aging with combined treatment plans that include surgical procedures
- Restoration and assisted hair transplantation treatments with biomaterials and growth factors
More than 16 experts in the field of regenerative medicine will be featured speakers at the event, including:
- Silvina Pastrana, Medical Director of Stem Cells Center Buenos Aires (Argentina), who will discuss stem cell therapy fundamentals and protocols in the medical office
- Jose Benitez, M.D., Medical Director of Boston Médical Group (Spain), whose lecture will focus on the most recent successful regenerative medicine clinical trial for treating erectile diffusion.
The World Symposium on Regenerative Medicine and Cell Therapies will be held Dec. 1, 2018 at the Marriott Hotel in Caracas, Venezuela. For more information and registration, visit the symposium website, email info@stemcellsgroup.com, or call +1305 560 5337.|
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine.
ISSCA serves its members through advancements made in the specialty of regenerative medicine.ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
About Global Stem Cells Group:
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations. Each corporation is focused on furthering scientific and technological advancements in cutting-edge stem cell research, development, treatment, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with an online, one-stop center for stem cell solutions that adhere to the highest medical standards.
Regenerative medicine symposium e Caracus Venezuela
- Published in Press Releases
Global Stem Cells Group launches “Regenerative Medicine” video blog on YouTube
Global Stem Cells Group announces the launch of the new “Regenerative Medicine” vlog featuring interviews with leaders in regenerative medicine.
MIAMI, Sept. 14, 2018–Global Stem Cells Group (GSCG), a word leader in regenerative medicine, has launched a new video blog (vlog) titled “Regenerative Medicine” on its YouTube channel. Physicians who incorporate regenerative medicine therapies in their patient treatments are invited to participate in the vlog.
The idea is to create a space for regenerative medicine practitioners to share their clinical experiences with viewers around the world. New interviews will be recorded and aired weekly on the “Regenerative Medicine” vlog.
The new vlog channel is part of Global Stem Cells Group’s ongoing effort to spread the word about the benefits of regenerative medicine therapies to viewers around the world and to provide practitioners with an opportunity to discuss their regenerative medicine practices with interested audiences, and stay abreast of what other practitioners in the field are doing.
According to Benito Novas, GSCG CEO, the vlog platform will provide an additional point of reference for physicians and patients looking for the latest information on stem cell research and therapies. It is also designed to help clarify the scope of stem cell procedures and to dispel myths and false information among audiences. All physicians who wish to participate in GSCG’s new vlog program will be included and encouraged to speak freely.
Physicians wishing to participate in an interview for the GSCG “Regenerative Medicine” vlog series are asked to email their CV and abstract to info@stemcellsgroup,com.
The Regenerative Medicine vlog will be posted on Global Stem Cells Group’s YouTube Channel and physician interviews will also be posted on the News ABout Cell Therapies blog.
For more information about Global Stem Cells Group, visit the GSCG website, email: info@stemcellsgroup.com, or call +1305 560 5337.
About Global Stem Cells Group:
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations. Each corporation is focused on furthering scientific and technological advancements in cutting-edge stem cell research, development, treatment, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop epicenter for stem cell solutions that adhere to the highest medical standards.
Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world
- Published in Press Releases
Regenerative medicine symposium hosted by ISSCA in Buenos Aires, Argentina Aug. 24, 2018, exceeds expectations organizers report
Organizers of the ISSCA regenerative medicine symposium “Applications of Cell Therapies in Medicine and Aesthetic Surgery” held in Buenos Aires, Argentina Aug. 24, 2018, featured 16 physicians traveling from six countries— Mexico, Chile, Colombia, Spain, Costa RIca and the U.S. —to serve as guest speakers.
MIAMI, Aug. 30, 2018—Enthused by the extraordinary success of the International Association for Stem Cell Applications (ISSCA)’s regenerative medicine symposium held at Universidad de Buenos Aires in Argentina Aug. 24, 2018, ISSCA organizers have already begun discussing plans to host the next conference in Miami in summer, 2019.
The 5th annual “Applications of Cell Therapies in Medicine and Aesthetic Surgery,” hosted 250 attendees and featured more than 16 speakers from six countries to discuss the latest clinical stem cell applications for a variety of therapies and treatments including traumatic injuries, pain management, neurological conditions, sports injuries, heart failure, erectile effusion, and aesthetic medicine procedures.
The symposium provided attendees with an opportunity to learn about the most important clinical applications of stem cell therapies from experienced regenerative medicine practitioners.
Leonardo Tacus, M.D., an arthroscopic surgeon specializing in orthopedics, traumatology, and regenerative medicine, spoke to attendees about clinical applications of regenerative medicine therapies to treat injuries sustained by professional athletes.
Jose Benitez, Medical Director of Boston Médical Group Spain. who specializes in male sexual dysfunctions. spoke about stem cell applications used to treat erectile dysfunction.
Calling the symposium their most successful regenerative medicine event to date, iSSCA members and conference speakers held an informative Q&A session lasting three hours until all questions were answered. The session covered a variety of compelling topics regarding stem cell therapies. A lecture based on the symposium will soon be available on ISSCA’s YouTube channel.
Information on the summer, 2019 symposium will be made available in upcoming weeks. For more information, visit stemcellconference.org website, email info@stemcellsgroup.com, or call +1305 560 5337.
About ISSCA:
International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training. and certification.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
###
regenerative medicine symposium Buenos Aires
- Published in Press Releases
Adimarket announces launch of Cellgenic stem cell protein extract hair restoration product
GSCG affiliate Adimarket announces the launch of the Cellgenic adipose-derived stem cell hair restoration application that maximizes the skin and hair follicles’ own revitalizing capabilities.
MIAMI, June 26, 2018—Global Stem Cells Group (GSCG) affiliate Adimarket announces the launch of the Cellgenic adipose-derived stem cells protein extract (CADPE) hair restoration application product.
CADPE combines refined growth factor proteins extracted from human adipose-derived stem cells in a conditioned media and a unique protein formula, to maximize the revitalizing characteristic of skin and hair follicles.
CADPE increases the reproduction of human follicles’ dermal papilla cells, which consist of a distinct population of specialized fibroblasts important in morphogenesis (differentiation and growth) of the hair follicle structure and control of the hair growth cycle, CADPE works by turning over dying skin cells at twice the frequency of normal skin,
CADPE benefits:
• Use of active proteins derived from human sources eliminates concerns with allergic reactions and skin irritation
• The natural composition of the product’s various growth factors acquired from adipose-derived stem cells can provide exceptional biological activity
• CADPE is multi-functioning, exhibiting anti-oxidation and hair re-growth effects
• Each growth factor has a pharmacological effect, but the combination of growth factors has a synergistic effect that can enhance the pharmacological action of single proteins.
• No special training is needed to learn how to use CADPE
• The CADPE application procedure is shorter than other hair restoration protocols, which can take up to eight hours per patient
• CADPE is supported by scientific evidence
When used by aesthetic practitioners, CADPE provides safe, cutting-edge hair thickening and hair follicle proliferation results that are CTFA-approved, take less application time than other hair restoration processes, and is backed by medical research.
Cellgenic adipose-derived stem cells protein extract can be purchased online at the Adimarket online store. For more information, visit the Adimarket website, email info@stemcellsgroup.com, or call 305-560-5337.
About Adimarket:
Adimarket, Inc., a division of the Global Stem Cells Group, is a one-stop, cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and healthcare professionals.
Adimarket was founded to provide practitioners the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting-edge treatments.
About Global Stem Cells Group:
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations. Each corporation is focused on furthering scientific and technological advancements in cutting-edge stem cell research, development, treatment, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop epicenter for stem cell solutions that adhere to the highest medical standards.
Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.
CADPE stem cell hair restoration application
- Published in Press Releases
ISSCA President Deyoung Kim, Ph.D., Announces Regenerative Medicine Symposium in Korea Nov. 24, 2018
ISSCA Founder and President Daeyong Kim, Ph.D., announces plans to host the Regenerative Medicine Cell Therapies Symposium in Seoul, Korea in November.
MIAMI, April 2, 2018—International Association for Stem Cell Application (ISSCA) President Daeyong Kim, Ph.D., has announced plans to host Applications of Cell Therapies in Medicine and Aesthetic Surgery, a regenerative medicine symposium, in Seoul Korea November 24, 2018.
The symposium will be ISSCA’s principal event for 2018, during which the organization will launch its entire 2019 program, including stem cell certification courses for physicians to be held in locations worldwide, as well as the 2019 regenerative medicine symposium agenda.
In 2019, ISSCA plans to expand its activities to Asia by hosting at least one regenerative medicine symposium and four stem cell certification courses during the year. The Korea symposium will be structured as a scientific meeting in which regenerative medicine practitioners share their clinical experience. ISSCA affiliate Global Stem Cells Group, and biomedical and leading lab equipment manufacturer N-Biotek will launch new technology for regenerative medicine practitioners.
The international symposium is part of ISSCA’s mission to support a paradigm shift in healthcare from traditional to regenerative medicine in the 21st Century and provide cutting-edge information on developments in all areas of stem cell research. The Buenos Aires event will host a group of renowned international speakers in the field of stem cell and regenerative medicine, who will offer a day of rigorous scientific discourse aimed at physicians.
Topics of focus at the symposium include:
- Management of aging at the cellular level
- Stem cell therapies in medical aesthetics: the latest methods of harvest and isolation Non-invasive protocols of non-surgical facial and body rejuvenation
- Beyond fillers and toxins
- Combined treatment plans that include surgical methods for the management of advanced aging
- Restoration and assisted hair transplantation with biomaterials and growth factors
- The invaluable role of biological cosmeceutical in the management of aging
- The aging process from the inside out: the role of hormones
- Management of the latest digital marketing tools for recruiting patients in their aesthetic clinics
The symposium will incorporate the biology, medicine, applications, regulations, product development, and commercialization of stem cells. Business opportunities, challenges, and potential strategies for overcoming these challenges will also be addressed.
To learn more about the ISSCA Korea symposium and to make a reservation, visit the stemcellconference.org website, email info@stemcellsgroup.com, or call +1305 560 5337.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training. and certification.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
ISSCA Korea regenerative medicine symposium
- Published in Press Releases
ISSCA to Host Regenerative Medicine Cell Therapies Symposium at Hotel Hyatt Regency, Istanbul, Turkey
ISSCA Istanbul conference: The International Association for Stem Cell Application (ISSCA) has announced plans to host a regenerative medicine symposium at the Hotel Hyatt Regency in Istanbul, Turkey April 28, 2018.
MIAMI, Feb 19, 2018—The International Association for Stem Cell Application (ISSCA) will host its next regenerative medicine symposium at the Hotel Hyatt Regency in Istanbul, Turkey April 28, 2018.
The symposium agenda will focus on:
- Molecular biology
- Clinical advances in stem cell research
- Models of treatment in surgical and cosmetic applications, and in clinical conditions
- Technological advances
- Application of minimally manipulated stem cells in the physician’s office
- Stem cells, regenerative medicine and its application in anti-aging medicine, Pain Management and Orthopedics
- Medical legal issues.
- Regulatory Pathways
Istanbul, the economic, cultural, and historic center of Turkey, is the country’s most populous city. The luxurious Hotel Hyatt Regency, located near Istanbul’s Ataturk Airport, offers visitors the combination of comfort, culture, and convenience for exploring the ancient city. Symposium attendees will be able to discover sights such as the Blue Mosque and the Hagia Sophia.
The Istanbul international symposium is part of ISSCA’s mission to support a paradigm shift from traditional healthcare solutions to regenerative medicine, and provide the latest innovative discoveries and developments in all areas of stem cell research. The symposium will host a group of renowned international speakers, experts in the field of stem cell and regenerative medicine, who will provide a full day of rigorous scientific discourse directed to physicians.
The day’s events will incorporate information on stem cell biology, medicine, applications, regulations, product development, and commercialization, business opportunities, challenges, and potential strategies for overcoming those challenges.
To participate in the ISSCA Istanbul Symposium, reserve your spot by registering today.
For more information, visit the stemcellconference.org website, email info@stemcellsgroup.com, or call +1305 560 5337.
About International Society for Stem Cells Applications
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
###
ISSCA Istanbul conference
- Published in Press Releases
Global Stem Cells Group Founder and CEO Benito Novas Recognized as a Leader in Regenerative Medicine
Image: Benito Novas
Global Stem Cells Group founder and CEO Benito Novas was recognized as a leader in regenerative medicine at the XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery and Obesity, Dec. 2, 2017, in Mexico City.
MIAMI, Dec. 22, 2017—Benito Novas, founder and CEO of Global Stem Cells Group (GSCG), earned recognition for his leadership in regenerative medicine at the XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery and Obesity, Dec. 2, 2017, in Mexico City.
Novas accepted the recognition, signed and presented to him by Congress President Rector Doctor Arturo Conde at the event, honoring him for helping thousands of physicians around the world bring regenerative medicine therapies to their clinical practices.
Novas provided training and equipment to physicians throughout South America, North America, Europe, Asia, and the Middle East through GSCG affiliate companies Stem Cell Training, Adimarket online regenerative medicine store, and Stem Cell Center Network (present in more than 30 cities globally).
Novas is a global entrepreneur, manager, and keynote speaker with expertise in the field of specialized marketing focused on biotechnology, life sciences, and healthcare development.
The philosophy that has driven him to launch and grow his companies is the desire for a perpetual flow of knowledge and innovation with regard to the role of stem cells in modern medicine.
“My aim is to accelerate the process of getting promising stem cell research and technology developed into treatments and therapies, and to make them readily available to benefit the health and well-being of a broad range of patients,” he says.
Using specialized marketing techniques focused on stem cells and their impact on the field of aesthetic surgery, Novas created a multi-company corporation based on his visionary approach to healthcare management and regenerative medicine.
To learn more about Global Stem Cells Group, visit the company website, email info@stemcellsgroup.com, or call 305-560-5337.
About Global Stem Cells Group:
Global Stem Cells Group (GSCG) Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
Global Stem Cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.
Benito Novas recognized
- Published in Press Releases
Adimarket, a Subsidiary of Global Stem Cells Group, to Distribute Alolotl Biologix Biological Products Worldwide
Adimarket, a subsidiary of Global Stem Cells Group, has announced an agreement with biotechnology company Alolotl Biologix to distribute biological products for regenerative medicine applications worldwide.
MIAMI, Dec.21, 2017— Adimarket, a subsidiary of Global Stem Cells Group (GSCG), and its subsidiary has announced an agreement with Phoenix, Arizona-based Alolotl Biologix to distribute the biotechnology company’s products for regenerative medicine applications worldwide.
Alolotl Biologix focuses on research to optimize the use of human biologicals and to develop biological-related products to foster regeneration and healing for a range of conditions, including orthopedic impairments, wound care, pain management, ophthalmic, cardiovascular, cosmetic, and more.
Adimarket will make the following amniotic liquid products available to qualified practitioners through its online store www.adimarket.net:
AxoBioFluid® C Amniotic Allograft Cryopreserved Liquid, cryopreserved liquid allograft derived from the amniotic membrane that provides structural tissue to advance soft tissue repair, replacement, and reconstruction. Product details:
- Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
- Immune privileged with anti-inflammatory and anti-bacterial properties
- A rich source of growth factors, proteins, cytokines, hyaluronic acid, and collagen scaffolds
- Contains extracellular matrix components for cellular attachment and proliferation
- Cryopreserved for an extended shelf life
AxoBioFluid® physician benefits
- Procedures are efficient and do not require special instrumentation.
• The use of AxoBioFluid® is billed as patient pays, which makes it a great alternative revenue source.
• A library of research papers to demonstrate efficacy degenerated tissue is provided.
AxoBioFluid® patient benefits
Relevant Conditions
AxoBioFluidâ C Amniotic Allograft Cryopreserved Liquid, cryopreserved liquid allograft derived from the amniotic membrane that provides structural tissue to advance soft tissue repair, replacement, and reconstruction. Product details:
- Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
- Immune privileged with anti-inflammatory and anti-bacterial properties
- A rich source of growth factors, proteins, cytokines, hyaluronic acid, and collagen scaffolds
- Contains extracellular matrix components for cellular attachment and proliferation
- Cryopreserved for an extended shelf life
AxoBioFluidâ physician benefits
- Procedures are efficient and do not require special instrumentation.
• The use of AxoBioFluid® is billed as patient pays, which makes it a great alternative revenue source.
• A library of research papers to demonstrate efficacy is provided.
AxoBioFluid® Amniotic Allograft Cryopreserved Liquid is a cryopreserved liquid allograft derived from the placental components of the amnion to advance soft tissue repair, replacement, and reconstruction. It is classified as minimally manipulated under FDA regulation 21 CFR Part 1271 and section 361 of the PHS. Benefits of AxoBioFluid® AxoBioFluid® is a human allograft fluid derived from the amniotic layer of the placenta. The two primary cell lines which reside in the amnion are human mesenchymal stromal cells (hMSC) and human amnion epithelial cells (hAEC). Both of these cells are considered to be pluripotent stem cells. AxoBioFluid® contains growth factors released while amniotic cells are grown in culture such as epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and transforming growth factor – beta (TGF-β). These proteins are essential for fetal growth and development and express significant therapeutic benefits when used as a treatment for various injuries and degenerative conditions. AxoBioFluid® is immuneprivileged, anti-inflammatory, anti-fibrotic, pro-vascular, and cytoprotective because of the cells being sourced from the amnion. These secreted factors also signal endogenous progenitor cells to promote regeneration and repair of damaged or degenerated tissue.
AxoBioFluid
- Degenerative disorders such as osteoarthritis
• Joint pain
• Inflammatory conditions such as: - Bursitis
- Tendonitis
- Fasciitis
- Epicondylitis
- Soft tissue injuries such as:
- Ligament & Tendon sprains
- Muscle & Meniscus tears
- Wound Care
AxoBioMembrane, a dehydrated allograft membrane patch derived from the amnion that advances wound repair, skin replacement, and reconstruction. Product details:
- Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
- Immune privileged with anti-inflammatory and anti-bacterial properties
- Contains extracellular matrix components for cellular attachment and proliferation
- Dehydrated and terminally e-beam sterilized for an extended shelf life.
AxoBioMembraneä Amniotic Allograft Membrane, like all allograft tissue products, has been subjected to recovery microbiological study and has been terminally sterilized with electron beam sterilization. It works by forming fibrin-elastin bonds at the wound site, ensuring excellent wound adherence. This generates a barrier that protects exposed nerve endings from irritants, providing pain relief while creating a favorable environment for tissue repair and regeneration. In addition, the AxoBioMembrane™ prevents excessive moisture loss by creating a vapor barrier at the wound surface. Growth factors present in the membrane are released into the wound bed, promoting angiogenesis leading to new blood supply needed for cellular migration, proliferation and ultimately, wound repair. Infection is one of the biggest concerns with chronic wounds. AxoBioMembrane™ functions as a bacteriostatic agent, which can inhibit the growth of bacteria at the wound site and reduce the rate infection. It has also been reported to have anti-fibrotic properties, which can reduce scarring. The membrane contains glycoprtoteins found exclusively in the amnion. AxoBioMembrane™ lacks specific surface antigens, which make it immune-privileged and anti-inflammatory.
AxoBioMembraneä physician benefits
- Procedures are efficient and do not require special instrumentation.
- AxoBioMembrane™ is billed as patient pays, which makes it a great alternative revenue source.
- We provide a library of research and white papers to demonstrate efficacy.
AxoBioMembraneä patient benefits:
- Pain Reduction
- Wound Adherence
- Less Scarring
- Faster Healing
- Neovascularization
- Wound Barrier
- Anti-bacterial
- Immune Privileged
AxoBio products are available to purchase on the Adimarket Website.
For more information, visit the Adimarket regenerative medicine online store website, email info@stemcellsgroup.com, or call 305-560-5337.
About Global Stem Cells Group:
Global Stem Cells Group (GSCG) Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.
About Adimarket:
Adimarket, Inc., a division of the Global Stem Cells Group, is a one-stop, cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals.
Adimarket was founded to provide practitioners the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting-edge treatments.
About Alolotl Biologix:
Axolotl Biologix, Inc. is an innovative biotechnology leader in regenerative medicine through research, technology and clinical application. Axolotl Biologix is expanding the human body’s ability to regenerate by developing and manufacturing regenerative human cell and tissue, medical technologies that are disrupting traditional, more invasive, painful, and expensive treatment protocols. For more information, visit www.axobio.com.
###
amniotic biofluid
- Published in Press Releases
- 1
- 2
